Cargando…
Considerations for use of direct oral anticoagulants in arterial disease
Cardiovascular diseases including coronary heart disease, stroke, and peripheral arterial disease were responsible for an estimated 18 million deaths in 2017. Despite advances in management over the past several decades, these patients continue to have substantial risk of subsequent cardiovascular e...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8162231/ https://www.ncbi.nlm.nih.gov/pubmed/34095731 http://dx.doi.org/10.1002/rth2.12502 |
_version_ | 1783700667651588096 |
---|---|
author | Siegal, Deborah M. Anand, Sonia S. |
author_facet | Siegal, Deborah M. Anand, Sonia S. |
author_sort | Siegal, Deborah M. |
collection | PubMed |
description | Cardiovascular diseases including coronary heart disease, stroke, and peripheral arterial disease were responsible for an estimated 18 million deaths in 2017. Despite advances in management over the past several decades, these patients continue to have substantial risk of subsequent cardiovascular events. We provide a narrative review of randomized clinical trials evaluating direct oral anticoagulants (DOACs) for the treatment of acute coronary syndromes, noncardioembolic ischemic stroke, embolic stroke of undetermined source, and peripheral arterial disease. In these conditions, considerations for use of single antiplatelet therapy, dual antiplatelet therapy, or low‐dose DOACs used together with antiplatelet therapy are presented. |
format | Online Article Text |
id | pubmed-8162231 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81622312021-06-03 Considerations for use of direct oral anticoagulants in arterial disease Siegal, Deborah M. Anand, Sonia S. Res Pract Thromb Haemost State of the Art Isth 2020 Cardiovascular diseases including coronary heart disease, stroke, and peripheral arterial disease were responsible for an estimated 18 million deaths in 2017. Despite advances in management over the past several decades, these patients continue to have substantial risk of subsequent cardiovascular events. We provide a narrative review of randomized clinical trials evaluating direct oral anticoagulants (DOACs) for the treatment of acute coronary syndromes, noncardioembolic ischemic stroke, embolic stroke of undetermined source, and peripheral arterial disease. In these conditions, considerations for use of single antiplatelet therapy, dual antiplatelet therapy, or low‐dose DOACs used together with antiplatelet therapy are presented. John Wiley and Sons Inc. 2021-05-28 /pmc/articles/PMC8162231/ /pubmed/34095731 http://dx.doi.org/10.1002/rth2.12502 Text en © 2021 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | State of the Art Isth 2020 Siegal, Deborah M. Anand, Sonia S. Considerations for use of direct oral anticoagulants in arterial disease |
title | Considerations for use of direct oral anticoagulants in arterial disease |
title_full | Considerations for use of direct oral anticoagulants in arterial disease |
title_fullStr | Considerations for use of direct oral anticoagulants in arterial disease |
title_full_unstemmed | Considerations for use of direct oral anticoagulants in arterial disease |
title_short | Considerations for use of direct oral anticoagulants in arterial disease |
title_sort | considerations for use of direct oral anticoagulants in arterial disease |
topic | State of the Art Isth 2020 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8162231/ https://www.ncbi.nlm.nih.gov/pubmed/34095731 http://dx.doi.org/10.1002/rth2.12502 |
work_keys_str_mv | AT siegaldeborahm considerationsforuseofdirectoralanticoagulantsinarterialdisease AT anandsonias considerationsforuseofdirectoralanticoagulantsinarterialdisease |